Published in:
Open Access
01-05-2020 | Human Immunodeficiency Virus | Original Article
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort
Authors:
Maria Giovanna Quaranta, Luigina Ferrigno, Monica Monti, Roberto Filomia, Elisa Biliotti, Andrea Iannone, Guglielmo Migliorino, Barbara Coco, Filomena Morisco, Maria Vinci, Roberta D’Ambrosio, Liliana Chemello, Marco Massari, Donatella Ieluzzi, Francesco Paolo Russo, Pierluigi Blanc, Gabriella Verucchi, Massimo Puoti, Maria Grazia Rumi, Francesco Barbaro, Teresa Antonia Santantonio, Alessandro Federico, Luchino Chessa, Ivan Gentile, Massimo Zuin, Giustino Parruti, Giulia Morsica, Loreta A. Kondili, on behalf of PITER Collaborating Group
Published in:
Hepatology International
|
Issue 3/2020
Login to get access
Abstract
Background
Liver disease progression after Hepatitis C Virus (HCV) eradication following direct-acting antiviral (DAA) treatment in the real-life setting according to Human Immunodeficiency Virus (HIV) coinfection was evaluated.
Methods
Patients consecutively enrolled in PITER between April 2014 and June 2019 and with at least 12-weeks follow-up following treatment were analysed. Cox regression analysis were used to evaluate HIV coinfection and factors independently associated with liver disease outcomes following viral eradication in DAA treated patients with pre-treatment liver cirrhosis.
Results
93 HIV/HCV coinfected and 1109 HCV monoinfected patients were evaluated during a median follow-up of 26.7 (range 6–44.6) and 24.6 (range 6.8–47.3) months, respectively. No difference in the cumulative HCC incidence and hepatic decompensation was observed between coinfected and monoinfected patients. Age (Hazard Ratio [HR] = 1.08; 95% CI 1.04–1.13), male sex (HR = 2.76; 95% CI 1.28–5.96), lower albumin levels (HR = 3.94; 95% CI 1.81–8.58), genotype 3 (HR = 5.05; 95% CI 1.75–14.57) and serum anti-HBc positivity (HR = 1.99, 95% CI 1.01–3.95) were independently associated with HCC incidence. Older age (HR = 1.03; 95% CI 1.00–1.07), male sex (HR = 2.13; 95% CI 1.06–4.26) and lower albumin levels (HR = 3.75; 95% CI 1.89–7.46) were independently associated with the appearance of a decompensating event after viral eradication.
Conclusion
Different demographic, clinical and genotype distribution between HIV coinfected vs those monoinfected, was observed in a representative cohort of HCV infected patients in Italy. Once liver cirrhosis is established the disease progression is decreased, but still persists regardless of viral eradication in both coinfected and monoinfected patients. In patients with cirrhosis, HIV coinfection was not associated with a higher probability of liver complications, after viral eradication.